NCHR submitted the only comment to CPSC about their proposed study of young children’s effective use of smart toys. CPSC responded to our previous comment and released a revised request for public comments, clarifying that the study was exploratory. We responded by again urging CPSC to study a larger number of children who are more representative of the U.S. population, to better guide future guidelines for these toys.
Read More »On Medical Treatments & Products
NCHR’s Comments on the CPSC’s Proposed Guidelines on Safety Standard for Infant and Infant/Toddler Rockers
NCHR supports the CPSC’s new proposed guidelines for infant rockers that will help to strengthen safety standards for such products. We offered suggestions to the rule, including adding a minimum age of use of at least 4 months old, more strongly discouraging the use of rockers for sleeping, and making physical changes that minimize the use for sleeping and the risk of injury. We also urged the CPSC to strengthen warning/labeling requirements, prevent stockpiling of rockers that don’t meet the new requirements, and support future research into the safety of rockers and related products.
Read More »NCHR Comments On FDA’s Draft Guidance Regarding the Confirmatory Evidence Needed to Demonstrate A Drug’s Effectiveness
December 18, 2023: NCHR urged the FDA to institute stronger scientific standards to confirm that a new drug is effective, preferably two randomized, double-blind, clinical control trials. Patients deserve drugs that are proven to work, not drugs that possibly work.
Read More »NCHR Comments On the FDA’s Draft Guidance Regarding the Development of Novel Drugs for Diabetic Foot Infections
December 18, 2023: NCHR urges the FDA to oppose using non-inferiority trials as evidence for new antibiotic treatments for diabetic foot infections. FDA defines “non-inferior” to include “slightly worse” but new antibiotic treatments should be better than standard treatments. Otherwise they don’t benefit patients and worsen antimicrobial resistance.
Read More »NCHR Comments on FDA’s Proposed Rule Regarding Canned Tuna Standard of Identity and Standard of Fill of Container
November 24, 2023: NCHR urges the FDA to address the issue of methylmercury exposure to children and pregnant women through canned tuna. We urge the FDA to reevaluate current standards and utilize clear labeling to inform consumers of the risk.
Read More »